Home / Pipeline / Zilovertamab vedotin + Rituximab + Cyclophosphamide + Doxorubicin + Rituximab Biosimilar + Prednisone + Prednisolone + Vincristine + Rescue medication Products Zilovertamab vedotin + Rituximab + Cyclophosphamide + Doxorubicin + Rituximab Biosimilar + Prednisone + Prednisolone + Vincristine + Rescue medication
Zilovertamab vedotin + Rituximab + Cyclophosphamide + Doxorubicin + Rituximab Biosimilar + Prednisone + Prednisolone + Vincristine + Rescue medication Phase 3 Recruiting ⚡ Active Interest: 47/100
Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Jan 27, 2025 → Mar 29, 2032
About Zilovertamab vedotin + Rituximab + Cyclophosphamide + Doxorubicin + Rituximab Biosimilar + Prednisone + Prednisolone + Vincristine + Rescue medication Zilovertamab vedotin + Rituximab + Cyclophosphamide + Doxorubicin + Rituximab Biosimilar + Prednisone + Prednisolone + Vincristine + Rescue medication is a phase 3 stage product being developed by Merck for Diffuse Large B-Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06717347. Target conditions include Diffuse Large B-Cell Lymphoma.
What happened to similar drugs? 1 of 20 similar drugs in Diffuse Large B-Cell Lymphoma were approved
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT06717347 Phase 3 Recruiting Jan 27, 2025 Mar 29, 2032 Diffuse Large B-Cell Lymphoma
Product Company Stage Hype Score IVA337 + Placebo Inventiva Phase 2 Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) Eli Lilly Phase 2 rituximab Celltrion Phase 1 YM155 Astellas Pharma Phase 2 enzastaurin + gemcitabine + rituximab + oxaliplatin Eli Lilly Phase 2 Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Johnson & Johnson Phase 2 VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Johnson & Johnson Phase 2 Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + Gemcitabine AbbVie Phase 3 ABBV-525 AbbVie Phase 1 rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab and lenalidomide + rituximab and bendamustine + rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin + gemcitabine and oxaliplatin + Epcoritamab + rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone + Lenalidomide + rituximab, ifosfamide, carboplatin, and etoposide phosphate + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Rituximab and Lenalidomide + Epcoritamab AbbVie Phase 1/2 Copanlisib + Venetoclax AbbVie Phase 1/2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 Epcoritamab + Lenalidomide AbbVie Phase 2 Venetoclax + Selinexor AbbVie Phase 1 Epcoritamab AbbVie Phase 1 Loncastuximab Tesirine and Epcoritamab AbbVie Phase 2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 bendamustine + navitoclax + rituximab AbbVie Phase 2 Epcoritamab AbbVie Phase 2 Epcoritamab (monotherapy) + Epcoritamab + Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + Gemcitabine and oxaliplatin + Epcoritamab (maintenance) + Rituximab and lenalidomide AbbVie Phase 1/2